SCHEMBL449928

SCHEMBL449928

O=[N+]([O-])c1cccc(S(=O)(=O)OC[C@H]2CO2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 1.00
WDR77 Q9BQA1 1/20 1.00
KMT2A Q03164 4/20 0.53
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
CA2 P00918 3/20 0.50
CA5A P35218 1/20 0.50
MEN1 O00255 3/20 0.49
LMNA P02545 1/20 0.47
MMP2 P08253 2/20 0.47
CA1 P00915 1/20 0.47
MMP1 P03956 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ACHE P22303 1/20 0.45
CYP19A1 P11511 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29481767 1.00 PRMT5 (1.00) PRMT5WDR77KMT2AGAAHTT
SCHEMBL336603 1.00 PRMT5 (1.00) PRMT5WDR77KMT2AGAAHTT
SCHEMBL29476299 1.00 PRMT5 (1.00) PRMT5WDR77KMT2AGAAHTT
SCHEMBL336605 1.00 PRMT5 (1.00) PRMT5WDR77KMT2AGAAHTT
SCHEMBL30301224 1.00 PRMT5 (1.00) PRMT5WDR77KMT2AGAAHTT
SCHEMBL28711197 0.90 PRMT5 (0.81) PRMT5WDR77KMT2AGAAHTT
SCHEMBL29481804 0.90 PRMT5 (0.81) PRMT5WDR77KMT2AGAAHTT
SCHEMBL29502671 0.90 PRMT5 (0.81) PRMT5WDR77KMT2AGAAHTT
SCHEMBL28692108 0.90 PRMT5 (0.81) PRMT5WDR77KMT2AGAAHTT
SCHEMBL8265917 0.88 PRMT5 (0.79) PRMT5WDR77KMT2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118126009-A Coumarin derivative, preparation method and application 成都纽瑞特医疗科技股份有限公司 2024-06-04 CN claimed
EP-2860175-B1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF TACURION (US) 2017-11-29 EP claimed
US-9598373-B2 Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method TACURION (US) 2017-03-21 US claimed
US-20150141641-A1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD ASTELLAS PHARMA INC. (JP) 2015-05-21 US claimed
EP-2860175-A1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF Astellas Pharma Inc. (JP) 2015-04-15 EP claimed
WO-2014140220-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES JANSSEN PHARMACEUTICA, N.V. (BE) 2014-09-18 WO claimed
US-20140275576-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 US claimed
US-7038062-B2 Synthesis of cyclic trithiocarbonates from epoxides THE GOODYEAR TIRE & RUBBER COMPANY (US) 2006-05-02 US claimed
US-20060004210-A1 SYNTHESIS OF CYCLIC TRITHIOCARBONATES FROM EPOXIDES GOODYEAR TIRE & RUBBER COMPANY, THE 2006-01-05 US claimed
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 US disclosed
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 US disclosed
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2025-06-19 US disclosed
US-12331035-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-06-17 US disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 US disclosed
EP-0454385-A1 Process for preparing optically active isomers of 6-substituted purinyl piperazine derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1991-10-30 EP disclosed
US-5053338-A Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer GLAXO INC. (US) 1991-10-01 US disclosed
WO-1991010642-A1 PROCESS FOR PREPARING HOMOCHIRAL AMINES AND PROCESS FOR PREPARING INTERMEDIATES FOR THE PREPARATION THEREOF, AND THE INTERMEDIATES PREPARED IN ACCORDANCE WITH THIS PROCESS NOBEL CHEMICALS AB (SE) 1991-07-25 WO disclosed
EP-0412814-A2 Pyridazinones having cardiotonic and beta blocking activity GLAXO WELLCOME INC. (US) 1991-02-13 EP disclosed
WO-1988000190-A1 OPTICALLY ACTIVE DERIVATIVES OF GLYCIDOL MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1988-01-14 WO disclosed
WO-1988000190-A1 OPTICALLY ACTIVE DERIVATIVES OF GLYCIDOL MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1988-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 158/4885KMT2A 155/4885
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 PRMT5 292/4885WDR77 368/4885KMT2A 38/4885
US-20150141641-A1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD AVPR2, AVPR1A, AVPR1B PRMT5 81/4885WDR77 3453/4885KMT2A 1807/4885
US-12331035-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 97/4885KMT2A 93/4885
US-20060004210-A1 SYNTHESIS OF CYCLIC TRITHIOCARBONATES FROM EPOXIDES TST, CXCR6, CCR6 PRMT5 1044/4885WDR77 847/4885KMT2A 636/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 PRMT5 3054/4885WDR77 1050/4885KMT2A 366/4885
US-20140275576-A1 PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES CYP1B1, CYP1A1, CYP4B1 PRMT5 4038/4885WDR77 2902/4885KMT2A 1117/4885
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, F2R, PF4 PRMT5 1562/4885WDR77 4530/4885KMT2A 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.